Material Safety Data Sheet Section 1. Identification of the substance Product Name: Cyclobutanecarbonitrile Synonyms: Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. H331: Toxic if inhaled H302: Harmful if swallowed H312: Harmful in contact with skin H226: Flammable liquid and vapour Keep away from heat/sparks/open flames/hot surfaces. No smoking P210: P261: Avoid breathing dust/fume/gas/mist/vapours/spray P280: Wear protective gloves/protective clothing/eye protection/face protection P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with water/shower P405: Store locked up Section 3. Composition/information on ingredients. Ingredient name: Cyclobutanecarbonitrile CAS number: 4426-11-3 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels, refrigerated. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data Melting point: No data Flash point: No data Density: No data Molecular formula: C5H7N Molecular weight: 81.1 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information UN Number: UN1992 Class: 3 Packing group: III Proper shipping name: FLAMMABLE LIQUIDS, TOXIC, N.O.S. (Cyclobutanecarbonitrile) Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
[EN] BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BIARYLAMIDE DE PRODUCTION DE LEUKOTRIÈNES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012082817A1
公开(公告)日:2012-06-21
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Parallel Synthesis of 1<i>H-</i>Pyrazolo[3,4-<i>d</i>]pyrimidines via Condensation of <i>N</i>-Pyrazolylamides and Nitriles
作者:Akshay A. Shah、Lois K. Chenard、Joseph W. Tucker、Christopher J. Helal
DOI:10.1021/acscombsci.7b00116
日期:2017.11.13
A novel parallel medicinal chemistry (PMC)-enabled synthesis of 1H-pyrazolo[3,4-d]pyrimidines employing condensation of easily accessible N-pyrazolylamides and nitriles has been developed. The presented studies describe singleton and library enablements that allowed rapid generation of molecular diversity to examine C4 and C6 vectors. This chemistry enabled access to challenging alkyl substituents
已开发出一种新颖的平行药物化学(PMC)合成1 H-吡唑并[3,4- d ]嘧啶的方法,该方法采用易于获得的N-吡唑烷基酰胺和腈的缩合反应。提出的研究描述了单例和库使能,其允许快速产生分子多样性来检查C4和C6载体。这种化学性质使人们能够使用具有挑战性的烷基取代基,从而扩大了整个化学空间,使其超过了典型的C(sp 2)–C(sp 2)偶联和S N Ar转化所能提供的空间。此外,讨论了允许使用更大和更多样化的酰胺和羧酸作为腈前体的单体基团互变。
[EN] DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES<br/>[FR] DÉRIVÉS D'AMIDES D'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-CARBOXYLIQUE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010141273A1
公开(公告)日:2010-12-09
Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
[EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2011097491A1
公开(公告)日:2011-08-11
Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
申请人:Merck Sharp & Dohme Corp.
公开号:US20180305320A1
公开(公告)日:2018-10-25
The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.